Trials / Completed
CompletedNCT03456349
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Nxera Pharma UK Limited · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care
Detailed description
This is a multi-centre study conducted in four countries. A total of 60 subjects with Alzheimer's disease who are on standard-of-care will be enrolled to receive one of 3 active HTL0018318 or placebo for a period of four weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTL0018318 | HTL0018318 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2018-07-16
- Completion
- 2018-07-16
- First posted
- 2018-03-07
- Last updated
- 2018-07-20
Locations
4 sites across 4 countries: Czechia, Poland, Slovakia, Spain
Source: ClinicalTrials.gov record NCT03456349. Inclusion in this directory is not an endorsement.